NCT03401268 - Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

May 1, 2019

Study Completion Date

May 1, 2019

Conditions

Hypogammaglobulinemia

Interventions

DRUG

subcutaneous immunoglobulin

24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto